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Abstract
Background: The hepatitis C virus (HCV) infection has been identified as a leading cause of progressive liver diseases worldwide.
Despite new treatment strategies, pegylated interferon alfa-2a (Peg-IFNα-2a), in combination with ribavirin (RBV), still represents
the gold standard of therapy for hepatitis C in developing countries.
Objectives: The aim of this study was to investigate the association of substitutions in the HCV subtype 1b (HCV-1b) core protein
and the rs12979860 polymorphism in the interleukin 28B gene (IL28B) with the response to Peg-IFNα-2a/RBV combination therapy
in Azerbaijani patients.
Patients and Methods: A total of fifty-one chronically HCV-1b-infected Azerbaijani patients were enrolled in this cross-sectional
study from March 2010 to June 2015. After RNA extraction from pre-treatment plasma, the core region of the HCV genome was am-
plified using the nested reverse transcription (RT) polymerase chain reaction (PCR) method, followed by standard sequencing. In
addition, genomic DNA was extracted from peripheral blood mononuclear cell (PBMC) specimens, and the rs12979860 single nu-
cleotide polymorphism (SNP) was identified using a PCR-restriction fragment length polymorphism (PCR-RFLP) assay.
Results: In this study, a significant association was observed between the non-responders and relapsers to antiviral therapy and
substitutions in the HCV-1b core region at positions 43 (R43K, P = 0.047), 70 (R70Q, P < 0.001), 91 (M91L, P = 0.037), and 106 (S106N, P
= 0.018). Concerning the IL28B polymorphism, the results showed that sustained virological response was significantly associated
with homozygous CC patients (P = 0.009) as compared with other genotypes, while homozygous TT subjects were associated with
HCV relapse after therapy (P = 0.006).
Conclusions: The data of the present study suggest that amino acid substitutions at position 43, 70, 91, and 106 in the HCV-1b core
protein are correlated with the response to the Peg-IFNα-2a/RBV treatment in Azerbaijani patients with chronic hepatitis C. More-
over, host genetic polymorphisms, such as those of the IL28B locus, might be useful for predicting the responsiveness to Peg-IFNα-
2a/RBV combination therapy against HCV.
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1. Background
The hepatitis C virus (HCV) infection has been iden-
tified as a leading cause of progressive liver diseases, in-
cluding cirrhosis and hepatocellular carcinoma (HCC) (1).
Despite the emergence of new treatment strategies for
chronic HCV infection (2), pegylated interferon alfa-2a
(Peg-IFNα-2a), in combination with ribavirin (RBV), still
represents the gold standard of therapy in developing
countries such as Azerbaijan. The response rate to this
treatment remains unsatisfactory, particularly in individu-
als infected with the HCV genotype 1b (HCV-1b), which rep-
resents the predominant genotype among Azerbaijani pa-
tients (3, 4).
Several host and viral parameters have been associated
with the response to interferon-based antiviral therapy.
Representative host factors include age, gender, ethnicity,
body mass index (BMI), grade of liver fibrosis and single nu-
cleotide polymorphisms (SNPs) in the IL28B gene (5, 6). Vi-
ral factors include HCV genotype, serum viral load, coinfec-
tion with human immunodeficiency virus (HIV) and sub-
stitutions in the core and NS5A region (7-10).
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Numerous reports indicate that the substitution of
arginine (R) with glutamine (Q) at amino acid position 70
(R70Q) of the core protein is significantly correlated with
a poor virological response to the Peg-IFNα-2a/RBV ther-
apy in patients infected with HCV-1b (11, 12). In addition,
it has been suggested that core 70 polymorphisms can be
used as predictive factors for the outcome of this combi-
nation treatment (13). However, to date, the occurrence of
core 70 substitution, and its association with treatment re-
sponse, has not been evaluated in Azerbaijani patients in-
fected with HCV-1b. Therefore, this deserves further inves-
tigation.
In addition to viral genetic variations, IL28B SNPs repre-
sent important host-related factors affecting the response
to Peg-IFNα-2a/RBV therapy (14, 15). In particular, patients
carrying the IL28B SNP rs12979860 CC genotype appear to
respond better to the antiviral therapy than those with the
rs12979860 CT/TT genotype (16, 17). Evaluation of both vi-
ral and host factors (variations in HCV core 70 and IL28B
rs12979860 polymorphisms) in pre-treatment samples of
Azerbaijani patients infected with HCV-1b can be informa-
tive in predicting the outcome of the therapy.
2. Objectives
The current study aimed to investigate the associa-
tion between the HCV core substitutions and the IL28B
rs12979860 polymorphisms with the response to Peg-IFNα-
2a/RBV therapy in Azerbaijani patients chronically infected
with HCV-1b.
3. Patients and Methods
3.1. Study Population
Fifty-one chronically HCV-1b infected Azerbaijani pa-
tients were enrolled in the current cross-sectional study be-
tween March 2010 and June 2015. These patients arrived in
the Islamic Republic of Iran for medical treatments from
the Republic of Azerbaijan and were visited in hospitals af-
filiated with the Iran University of Medical Sciences.
Patients aged over thirteen years, and with HCV RNA
levels in their plasma ≥ 450 IU/mL for a period of six
months prior to the present study, were considered eli-
gible. Patients co-infected with HIV or hepatitis B virus
(HBV) were excluded, as were subjects affected by HCC,
liver dysfunction, liver transplants, decompensated liver
disease, poorly-controlled psychiatric diseases, creatinine
clearance rate of 50 mL/minute, malignant neoplastic dis-
ease, active substance abuse, severe cardiac or chronic pul-
monary disease, or poorly-controlled diabetes (18). This
study was approved by the ethical committee of the Iran
University of Medical Sciences (Tehran, Iran). All patients
provided written informed consent prior to study partic-
ipation and were treated with a combinational therapy of
RBV (1,000 - 1,200 mg/day) (Copeguss, Roche, Basel, Switzer-
land) and Peg-IFNα-2a (180 µg/week) (Pegasyss, Roche,
Basel, Switzerland) for 48 weeks.
3.2. Established Responses to the Treatment
Patients with sustained virological response (SVR),
such as those displaying undetectable HCV RNA levels at
the end of the therapy and during the six months follow-
up period, were defined as responders. Patients whose
HCV-RNA levels were still detected at the end of the antivi-
ral therapy were considered non-responders (NR), while
those who had undetectable HCV-RNA levels at the end of
treatment, followed by a reappearance of viremia over the
six months follow-up period, were designated as relapsers.
Both non-responders and relapsers were considered non-
viral response (NVR) patients. Finally, patients with un-
detectable HCV RNA levels at 12 and 4 weeks of treatment
were defined as early viral response (EVR) and rapid viral
response (RVR), respectively (19, 20).
3.3. Specimens Collection and Processing
At the beginning of the treatment, approximately 5 mL
samples of whole peripheral blood were collected from
each patient and kept in sterile vacutainer tubes con-
taining ethylenediaminetetraacetic acid (EDTA). Following
plasma separation, peripheral blood mononuclear cells
(PBMCs) were isolated from peripheral blood using Ficoll-
density gradient centrifugation (Lympholyte H, Cedarlane,
Hornby, Canada). After three washes with phosphate-
buffered saline (pH = 7.3±0.1), PBMCs were counted, resus-
pended in 200 µL RNAlater solution (Ambion, Inc, Austin,
Texas, USA), and stored at -80°C until use.
3.4. RNA Isolation and Complementary DNA (cDNA) Synthesis
Viral RNA was extracted from 200 µL plasma samples
using the high pure viral nucleic acid Kit (Roche Diagnos-
tics GmbH, Mannheim, Germany), according to the manu-
facturer’s instructions. The quantity and quality of the iso-
lated RNA were measured using the NanoDrop spectropho-
tometer (Thermo Scientific, Wilmington, USA), and 0.5 mg
of the total RNA, with an A260/A280 ratio≥ 1.90, was used
for cDNA synthesis, as previously described (4, 19, 21)
3.5. Hepatitis C Virus RNA Quantitation and Genotyping
HCV viral load was assessed using the COBAS TaqMan
HCV Test v2.0 (Roche Molecular Diagnostics, Mannheim,
Germany) real-time PCR. HCV genotyping was carried out
using restriction fragment length polymorphism (RFLP)
assay of the 5′ noncoding region (5′-NCR) of the viral
genome, according to a previously described protocol (22).
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3.6. Amplification of the HCV Core Region Using Reverse
Transcriptase-Nested Polymerase Chain Reaction (RT-Nested
PCR)
The HCV core region (nucleotides 340 - 682) was
subjected to nested PCR using the following primers:
outer sense 274F (5′-AAGGCCTTGTGGTACTGCCTG-3′), outer
antisense oka186R (5′-ATGTACCCCATGAGGTCGGC-3′), in-
ner sense 318F (5′-GGAGGTCTCGTAGACCGTGCA-3′) and in-
ner antisense 709R (5′-GACCTTACCCAARTTMCGCGACCTA-
3′) (23).
The first and second rounds of nested PCR were carried
out in a 25 µL mixture reaction containing 1.0 U of Ex Taq
DNA polymerase [TaKaRa Biotechnology (Dalian) Co., Ltd.,
Shiga, Japan], 2.5 µL of 10X Ex Taq buffer (Mg2+ free), 2.0 µL
of MgCl2 (25 mM), 2.0 µL dNTPs Mixture (25 mM each) and
10 pmol of each outer primer. In addition, 2.5 µL of DNA
was added to the mixture for the first round of nested PCR
while, for the second one, 2.5 µL of the resulting PCR prod-
uct was used as a template. For the first round, PCR con-
ditions were as follows: initial denaturation at 95°C for 5
minutes, 35 cycles of 30 s at 95°C, 45 s at 60°C, and 60 s at
72°C, followed by a final extension of 7 minutes at 72°C. The
second round of PCR was conducted as follows: initial de-
naturation at 95°C for 5 minutes, 35 cycles of 30 s at 95°C,
30 s at 60°C, and 50 s at 72°C, followed by a final extension
of 7 minutes at 72°C.
The second round PCR products were purified using
the high pure PCR product purification kit (Roche Diag-
nostic, Mannheim, Germany), according to the manufac-
turer’s instruction. Next, the samples were sequenced bi-
directionally, according to the dye termination method,
using the ABI 3730 XL sequencer. The sequences of the
HCV Core region were determined from the pre-treatment
plasma of the fifty-one Azerbaijani patients with chronic
HCV-1b infection.
3.7. Genotyping of the IL28B rs12979860 C/T Polymorphism
Genomic DNA was extracted from PBMC samples using
the QIAamp DNA blood mini kit (Qiagen GmbH, Hilden,
Germany), according to the manufacturer’s instructions.
Genotyping of the IL28B rs12979860 C/T polymorphism was
conducted using PCR-based RFLP assay as described previ-
ously (24).
3.8. Sequence Analysis of the HCV Core Region
A consensus sequence of the core region was gener-
ated by aligning all of the nucleotides encoding the core
amino acid residues obtained from the current study to
the HCV-1b reference genome (GenBank accession num-
ber D90208), using MEGA software (version 6.0). The phy-
logenetic tree of the core amino acid residues (codons
1 - 122) was inferred by aligning the sequences obtained
from the pre-treatment plasma samples of responders,
non-responders (NR) and relapsers with the HCV-1b refer-
ence genome according to the Neighbor-Joining method,
using MEGA software (version 6.0) (Figure 1). Statistical sig-
nificance of the phylogenetic trees was assessed using the
bootstrap method (one thousand replicates).
3.9. The Accession Numbers of Nucleotide Sequences
The nucleotide sequences of the HCV-1b core region
presented in this study were submitted to GenBank, and
will be available with the accession numbers KT329291 to
KT329341.
3.10. Statistical Analysis
All calculations were performed using the SPSS soft-
ware package (SPSS Inc., Chicago, IL, USA). The normality
of the data was assessed using the Kolmogorov-Smirnov
test. The analysis of continuous variables was carried out
using the One-way ANOVA and the Kruskal-Wallis tests. The
χ2-test was employed to evaluate the associations between
categorical variables. A P ≤ 0.05 was considered statisti-
cally significant.
4. Results
4.1. Baseline Characteristics
Fifty-one Azerbaijani patients, chronically infected
with HCV-1b, were enrolled in this prospective study. The
mean age of participants was 39.6 ± 10.6 (range 20 - 58
years). Twenty-two (43.1%) out of fifty-one patients were
male. The demographic features, laboratory parameters,
and different responses to the Peg-IFNα-2a/RBV combina-
tion therapy (responders [n = 32, 62.7%], NR [n = 7, 13.3%], re-
lapsers [n = 12, 23.5%]) are summarized in Table 1.
Significant differences were observed in terms of gen-
der (P = 0.018), viral load titer (P = 0.020) and aspartate
aminotransferase (AST) level (P = 0.024) but not for age (P
= 0.547) or alanine aminotransferase (ALT) level (P = 0.992)
(Table 1).
4.2. HCV Core Substitutions and Treatment Response
The core region of HCV-1b was amplified, sequenced
and aligned with the HCV-1b reference genome (GenBank
accession number D90208) (Figure 1). In the present study,
a significant association was observed between the out-
come of the antiviral therapy and amino acid substitutions
in the HCV-1b core region at positions 43 [arginine (R) to ly-
sine (K), P = 0.047], 70 [R to glutamine (Q), P < 0.001], 91
[methionine (M) to leucine (L), P = 0.037], and 106 [Serine
(S) to Asparagine (N), P = 0.018]. In contrast, no association
Hepat Mon. 2016; 16(5):e35597. 3
Bokharaei-Salim F et al.
A
 
 
B
F-3 SVR
F-4 SVR
P-6 SVR
P-7 SVR
P-8 SVP
P-10 SVR
P-12 SVR
P-13 SVR
P-15 SVR
P-15 SVR
P-15 SVR
P-15 SVR
P-20 SVR
P-21 SVR
P-24 SVR
P-26 SVR
P-28 SVR
P-30 SVR
P-31 SVR
F-33 SVR
P-35 SVR
F-36 SVR
F-40 SVR
F-41 SVR
P-43 SVR
F-45 SVR
F-46 SVR
F-47 SVR
F-4B SVR
F-49 SVR
P-50 SVR
P-51 SVR
P-5 NR
P-9 NR
P-17 NR
P-22 NR
P-27 NR
P-34 NR
P-36 NR
P-1 Relapse
P-2 Relapse
P-11 Relapse
P-14 Relapse
P-23 Relapse
P-25 Relapse
P-29 Relapse
F-32 Relapse
F-37 Relapse
F-39 Relapse
F-42 Relapse
F-44 Relapse
Amino Acid Sequences of Core (Codons 1-122)
Amino Acid Sequences of Core (Codons 1-122)
P-3 SVR
P-4 SVR
P-6 SVR
P-7 SVR
P-8 SVR
P-10 SVR
P-12 SVR
P-13 SVR
P-15 SVR
P-16 SVR
p-18 SVR
P-19 SVR
P-20 SVR
P-21 SVR
P-24 SVR
P-26 SVR
P-28 SVR
P-30 SVR
P-31 SVR
P-33 SVR
P-35 SVR
P-38 SVR
P-40 SVR
P-41 SVR
P-43 SVR
P-45 SVR
P-46 SVR
P-47 SVR
P-48 SVR
P-49 SVR
P-50 SVR
P-51 SVR
P-5 NR
P-9 NR
P-17 NR
P-22 NR
P-27 NR
P-34 NR
P-36 NR
P-1 Relapse
P-2 Relapse
P-11 Relapse
P-14 Relapse
P-23 Relapse
P-25 Relapse
P-29 Relapse
P-32 Relapse
P-37 Relapse
P-39 Relapse
P-42 Relapse
P-44 Relapse
D90208.1HCV-lb        M  S  T  N  P  K  P  Q R  K        T K  R  N  T N  R  R  P  Q      D  V  K  F  P  G  G G Q            V  G  G V  Y   L  L  P  R   R      G  P  R  L  G  V  R  A  T  R      K   T  S  E  R  S  Q  P  R  G       R  R  Q P   I  P   K  A  R  R
D90208.1 HCV-lb       P   E  G  R  T W A  Q P  G       Y  P  W P  L   Y  G N  E  G      M G W A  G W L  L   S   P      R  G  S  R  P  S  W G  P  T      D  P  R  R  R  S  R  N  L  G      K   V
10 20 30 40 50 60 70
1201101009080
Figure 1. Sequences of the Core Amino Acid Residues (codons 1 - 122) obtained From the Pre-Treatment Plasma of Responders (Indicated as SVR), Non-Responders (NR) and
Relapsers Aligned to the HCV-1b Reference Genome (GenBank Accession Number D90208)
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Table 1. Demographic and Laboratory Parameters of the Azerbaijani Patients Infected With HCV-1b and the Different Responses to the Peg-IFNα-2a/RBV Antiviral Therapy
Patients Sustained Virological
Responsers
Non-Responders Relapsers Total P Value
No. (%) 32 (62.7) 7 (13.7) 12 (23.5) 51 (100)
Gender 0.018a
Male 14 0 8 22
Female 18 7 4 29
Mean age, Y 38.8± 10.5 (23 - 58) 43.7± 7.5 (36 - 52) 39.3± 12.5 (20 - 57) 39.6± 10.6 (20 - 58) 0.547
Laboratory Parameters
Median Viral Load (IU/mL) 1,017,040 (113,829 -
23,800,950)
408,489 (119,770 - 575,030) 1,092,631 (139,622 - 1,572,297) 801,990 (113,829 - 23800,950) 0.020a
Median ALT (IU/L) 50.0 (21 - 121) 50.0 (42 - 64) 46.0 (30 - 180) 50.0 (21 - 180) 0.992
Median AST (IU/L) 42.0 (22 - 168) 39.0 (26 - 67) 47.0 (43 - 156) 44.0 (22 - 168) 0.024a
Abbreviations: ALT, Alanine aminotransferase; AST, Aspartate aminotransferase.
aStatistically significant.
was observed between the outcome of the Peg-IFNα-2a/RBV
treatment and amino acid substitutions at residues 20 [Q
to leucine (L)], 30 [isoleucine (I) to T], and 101 [R to Histidine
(H)] (Table 2).
A phylogenetic tree was labelled with patient numbers
and responses to the Peg-IFNα-2a/RBV treatment. It is note-
worthy that most of relapsers are clustered in one of the
clades (Figure 2). No clustering was observed in other se-
quences, according to treatment response.
4.3. Single Nucleotide Polymorphisms (SNPs) of the IL28B Geno-
type
Twelve (23.5%), thirty-six (70.6%) and three (5.9%) out of
fifty-one patients possessed, respectively, the CC, CT and TT
genotypes of IL28B rs12979860. Interestingly, all of the ho-
mozygous CC patients achieved SVR, whereas TT homozy-
gous patients were found exclusively in relapsers. Twenty
out of thirty-six CT heterozygous patients (62.5%) showed
SVR. It is noteworthy that the CC genotype was associated
with SVR (P = 0.009), while the TT genotype was associated
with a relapse response (P = 0.006) (Table 3).
5. Discussion
It is known that host factors (e.g. IL28B polymorphisms,
innate immunity) and viral factors (e.g. HCV genotypes,
amino acid variation in the HCV core and NS5A regions)
might affect the outcome of the Peg-IFNα-2a/RBV combi-
nation therapy (17, 25-27). Analysis of various regions of
the HCV genome has shown differences in amino acid
residues between non-responders and responders to HCV
treatment (28). Several studies indicate that amino acid
substitutions at positions 70 and 91 of the core region rep-
resent important pre-treatment factors associated with vi-
rological non-response to Peg-IFNα-2a/RBV combination
therapy. In particular, substitutions of arginine (R) with
glutamine (Q) at position 70 (R70Q) and/or leucine (L) with
methionine (M) at position 91 (L91M) were significantly
common in virological non-responders (8).
In the present study, the occurrence of the R70Q sub-
stitution in the core region was significantly higher (P <
0.001) in non-responders and relapsers than in the rest
of the patients. Similarly, a significant association be-
tween the R70Q substitution and the outcome of the Peg-
IFNα-2a/RBV combination therapy in non-responders pa-
tients infected with HCV-1b has been reported by several
previous studies (12, 23, 29, 30). Additionally, several re-
ports indicated that the frequency of substitutions in the
core residue at position 91 was significantly higher in non-
responders than in responders or relapsers (12, 29). It is
noteworthy that in this study, a significant correlation was
observed between the outcome of Peg-IFNα-2a/RBV com-
bination therapy and the L91M substitution (P = 0.037).
Therefore, it seems that the core 70 and 91 polymorphisms
can be used as pre-treatment factors to predict the re-
sponse to the Peg-IFNα-2a/RBV combination therapy. Over-
all, the results obtained in this study indicate that core vari-
ability might influence the treatment response in Azerbai-
jani patients.
Interestingly, in the present study, a significant associa-
tion was observed between the amino acid substitution at
position 43 of the core (R43K) and HCV non-response and
relapse (P = 0.047). A significant association was also seen
between the amino acid substitution at position 106 of the
core (S106N) and HCV SVR (P = 0.018) after Peg-IFNα-2a/RBV
Hepat Mon. 2016; 16(5):e35597. 5
Bokharaei-Salim F et al.
Table 2. Correlation Between Substitutions in HCV-1b Core Amino Acid Residues and Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients
Substitutions in Core Protein Sustained Virological Responders Non-Responders and Relapsers Total P Value
No. (%) 32 (62.7) 19 (37.3) 51 (100)
Substitution in codon 20 (Q to L) 4 (12.5) 0 (0.0) 4 (7.8) 0.276
Substitution in codon 30 (I to T) 3 (9.4) 0 (0.0) 3 (5.9) 0.388
Substitution in codon 43 (R to K) 0 (0.0) 3 (15.8) 3 (5.9) 0.047a
Substitution in codon 70 (R to Q) 0 (0.0) 15 (79.0) 15 (29.4) < 0.001a
Substitution in codon 91 (M to L) 7 (21.9) 0 (0.0) 7 (13.7) 0.037a
Substitution in codon 101 (R to H) 5 (15.6) 0 (0.0) 5 (9.8) 0.143
Substitution in codon 106 (S to N) 9 (28.1) 0 (0.0) 9 (17.6) 0.018
Abbreviations: H, Histidine; I, Isoleusine; K, Lysine; L,Leucine; M, Methionine; N, Asparagine; R, Arginine; Q, Glutamine; S, Serine; T, Threonine.
aStatistically significant.
Table 3. Correlation Between IL28B Polymorphisms (rs12979860) of HCV-1b and Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patientsa
IL28B Polymorphisms (rs12979860) Sustained Virological Responders Non-Responders Relapsers Total P Value P Value
No. (%) 32 (62.7) 7 (13.7) 12 (23.5) 51 (100)
CC 12 (37.5) 0 (0.0) 0 (0.0) 12 (23.5) 0.009 0.001
CT 20 (62.5) 7 (100.0) 9 (75.0) 36 (70.6) 0.133 0.001
TT 0 (0.0) 0 (0.0) 3 (25.0) 3 (5.9) 0.006 0.001
aStatistically significant.
combination therapy.
It should be noted that these correlations have never
been reported in previous reports. Therefore, it appears
that the polymorphism at position 43 of the core can
most likely be a useful pre-treatment predictor of HCV
non-response and relapse, while the polymorphism at po-
sition 106 of the core can most likely serve as a useful
pre-treatment predictor of HCV SVR after Peg-IFNα-2a/RBV
combination therapy in patients infected with HCV-1b.
However, more studies should be conducted to confirm
this association.
Earlier studies have shown that the HCV core region
may be related with resistance to the antiviral effects of
IFN, which mediates the Janus kinase-STAT (JAK-STAT) sig-
nalling cascade (31-33). This study found that amino acid
substitutions in the HCV-1b core region may be used to pre-
dict the virological non-response to the Peg-IFNα-2a/RBV
therapy by HCV-1b infected patients. Thus, the data ob-
tained from the present study suggest that substitutions
in the HCV-1b core counteract the IFN antiviral effects. Nev-
ertheless, more studies are needed to determine the func-
tional and structural impact of amino acid substitutions at
position 43, 70, 91, and 106 of the core during the Peg-IFNα-
2a/RBV therapy to confirm the above finding.
Interleukin 28B is a Type 1 helper (Th1) cytokine that
belongs to the type-III IFN family, a class-II cytokine recep-
tor ligand, and also named IFN-k. IL-28B plays an impor-
tant role in the regulation of interferon-stimulated gene
(ISG) expression (34, 35). It is produced by dendritic cells,
as well as PBMCs, upon viral infection. It is recognized that
IL-28B exhibits antiviral activity and has an effect on the
natural clearance of HCV (36). This study was conducted
to assess the effect of rs12979860, a SNP located near IL28B,
on the outcome of Peg-IFNα-2a/RBV combination therapy.
Consistent with previous studies (15, 16), the frequency
of the IL28B CC genotype in responders was significantly
higher (37.5%) than the CT (0.0%) or TT (0.0%) genotypes (P
= 0.009). Thus, it seems that the rs12979860 C allele con-
fers some advantages in terms of response to the Peg-INFα-
2a/RBV combination therapy against HCV infection. Over-
all, these data indicate that host genetics might be useful
for predicting treatment response to HCV infection (16).
In conclusion, the current study has demonstrated
that amino acid substitutions at position 43, 70, 91, and
106, of the HCV-1b core region and the rs12979860 polymor-
phism (located 3 kb upstream of IL28B) are associated with
the outcome of Peg-IFNα-2a/RBV combination therapy in
Azerbaijani patients with chronic HCV infection. In gen-
eral, it is notable that the amino acid residue sequence in
the HCV-1b core region and the IL28B allelic pattern play
6 Hepat Mon. 2016; 16(5):e35597.
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P-6   (SVR)
P-28   (SVR)
P-36   (NR)
P-22   (NR)
P-39   (Relapse)
P-1   (Relapse)
P-23   (Relapse)
P-29   (Relapse)
P-14   (Relapse)
P-37   (Relapse)
P-11   (Relapse)
P-25   (Relapse)
P-32   (Relapse)
P-44   (Relapse)
P-9   (NR)
P-2   (Relapse)
P-42   (Relapse)
P-48   (SVR)
P-19   (SVR)
P-46   (SVR)
P-15   (SVR)
P-30   (SVR)
0.01
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86
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75
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80
Figure 2. Phylogenetic Tree Based on the Core Amino Acid Sequences (Codons 1 - 122) Obtained From Pre-Treatment Plasma of Responders (Indicated as SVR), Non-Responders
(NR) and Relapsers, Aligned With the HCV-1b Reference Genome (GenBank Accession Number D90208)
important roles in determining the response to Peg-IFNα-
2a/RBV combination therapy.
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